Archive for 2019

  • Patent approved in Japan for Isofol’s drug candidate arfolitixorin

    GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL). A patent covering the Active…

    by
  • Patent detecting how patients respond to folate-based cancer treatment approved in the USA

    GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announces the approval from…

    by
  • Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia

    GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion…

    by
  • Isofol’s board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company

    GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that the board…

    by

  • Warning: getimagesize(/home/isofolme/public_html/wp-content/uploadshttps://www.pharmasalmanac.com/hubfs/2236109/PA_logo_Hoz_2019.svg): failed to open stream: No such file or directory in /home/isofolme/public_html/wp-content/themes/joyn/includes/plugins/aq_resizer-1x.php on line 80

    Pharma’s Almanac – Round table

    Our CEO, Anders Rabbe, was featured twice in Pharma’s Almanac Q3 issue in its “Round table” segment. He discussed the…

    by
  • Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer

    GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion…

    by
  • Poster ESMO 2019

    Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress GOTHENBURG,…

    by
  • Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress

    GOTHENBURG, Sweden, September 29, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced a poster presentation…

    by
  • Published abstract at ESMO

    Published abstract at ESMO “Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic…

    by
  • Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress

    Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress GOTHENBURG, Sweden, September 12, 2019…

    by